文献速递慢性肾脏病肾小球疾病血液净化与透析

血浆炎症生物标志物与组织病理病变、肾病进展及死亡的关联:波士顿肾脏活检队列研究

The Associations of Plasma Biomarkers of Inflammation With Histopathologic Lesions, Kidney Disease Progression, and Mortality-The Boston Kidney Biopsy Cohort Study.
PubMed 文献 · Kidney Int Rep · 2021-01-06

该前瞻性观察队列纳入523例接受原生肾脏活检的患者,检测sTNFR-1、sTNFR-2、YKL-40、MCP-1和suPAR五种血浆炎症标志物。sTNFR-1、sTNFR-2、MCP-1和suPAR与肾小管间质及肾小球病变相关,sTNFR-1、sTNFR-2、YKL-40和MCP-1与肾病进展风险升高相关。

要点

  • sTNFR-1、sTNFR-2、MCP-1、suPAR与肾小管间质和肾小球病变相关,YKL-40校正后无关联。
  • sTNFR-1、sTNFR-2、YKL-40、MCP-1每翻倍与肾病进展风险升高相关,HR 1.21–1.47。
  • sTNFR-2、YKL-40、MCP-1每翻倍与死亡风险升高相关,HR 1.33–1.45;suPAR与进展和死亡无显著关联。

核心结论

  • sTNFR-1、sTNFR-2、YKL-40、MCP-1和suPAR在多种肾脏疾病中与组织病理病变及不良临床结局相关。

研究设计与样本

  • 前瞻性观察队列研究,纳入523例在3家三级医院接受临床指征原生肾脏活检的患者。
  • 由两名肾脏病理医师对活检标本进行半定量组织病理评分。
  • 采用比例风险模型检验生物标志物与肾病进展(eGFR下降≥40%或ESKD复合终点)及死亡的关联。

主要发现

  • 平均eGFR为56.4±36 ml/min per 1.73 m2,中位蛋白尿(IQR)为1.6(0.4, 3.9)g/g肌酐。
  • 最常见原发临床病理诊断:增生性肾小球肾炎29.2%、非增生性肾小球病18.1%、晚期肾小球硬化11.3%、糖尿病肾病11.1%。
  • sTNFR-1、sTNFR-2、MCP-1和suPAR与肾小管间质及肾小球病变相关;YKL-40多变量校正后与任何组织病理病变均无关联。
  • 中位随访65个月,182例发生肾病进展、85例死亡。
  • 多变量校正后,sTNFR-1、sTNFR-2、YKL-40和MCP-1每翻倍与肾病进展风险升高相关(HR 1.21–1.47);sTNFR-2、YKL-40和MCP-1每翻倍与死亡风险升高相关(HR 1.33–1.45);suPAR与肾病进展或死亡无显著关联。

临床怎么用

  • 在多种肾脏疾病中,可考虑将sTNFR-1、sTNFR-2、YKL-40、MCP-1作为评估肾病进展和死亡风险的炎症标志物。
  • suPAR虽与组织病理病变相关,但与肾病进展和死亡无显著关联,临床解读需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Soluble tumor necrosis factor receptor (sTNFR)-1, sTNFR-2, YKL-40, monocyte chemoattractant protein (MCP)-1, and soluble urokinase plasminogen activator receptor (suPAR) have emerged as promising biomarkers of inflammation but have not been evaluated across diverse types of kidney diseases. METHODS: We measured these plasma biomarkers in 523 individuals enrolled into a prospective, observational cohort study of patients undergoing clinically indicated native kidney biopsy at 3 tertiary care hospitals. Two kidney pathologists adjudicated biopsy specimens for semiquantitative scores of histopathology. Proportional hazard models tested associations between biomarkers and risks of kidney disease progression (composite of ≥40% estimated glomerular filtration rate [eGFR] decline or end-stage kidney disease [ESKD]) and death. RESULTS: Mean eGFR was 56.4±36 ml/min per 1.73 m2 and the median proteinuria (interquartile range) was 1.6 (0.4, 3.9) g/g creatinine. The most common primary clinicopathologic diagnoses were proliferative glomerulonephritis (29.2%), nonproliferative glomerulopathy (18.1%), advanced glomerulosclerosis (11.3%), and diabetic kidney disease (11.1%). sTNFR-1, sTNFR-2, MCP-1, and suPAR were associated with tubulointerstitial and glomerular lesions. YKL-40 was not associated with any histopathologic lesions after multivariable adjustment. During a median follow-up of 65 months, 182 participants suffered kidney disease progression and 85 participants died. After multivariable adjustment, each doubling of sTNFR-1, sTNFR-2, YKL-40, and MCP-1 was associated with increased risks of kidney disease progression, with hazard ratios ranging from 1.21 to 1.47. Each doubling of sTNFR-2, YKL-40, and MCP-1 was associated with increased risks of death, with hazard ratios ranging from 1.33 to 1.45. suPAR was not significantly associated with kidney disease progression or death. CONCLUSIONS: sTNFR-1, sTNFR-2, YKL-40, MCP-1, and suPAR are associated with underlying histopathologic lesions and adverse clinical outcomes across a diverse set of kidney diseases.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Srivastava A, Schmidt IM, Palsson R, et al. The Associations of Plasma Biomarkers of Inflammation With Histopathologic Lesions, Kidney Disease Progression, and Mortality-The Boston Kidney Biopsy Cohort Study. Kidney Int Rep. 2021. PMID: 33732983. doi:10.1016/j.ekir.2020.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。